[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biolinerx Ltd ADR (BLRX)

Biolinerx Ltd ADR (BLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,721
  • Shares Outstanding, K 4,368
  • Annual Sales, $ 1,180 K
  • Annual Income, $ -1,180 K
  • EBIT $ -11 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.53
  • Price/Sales 12.85
  • Price/Cash Flow N/A
  • Price/Book 0.72

Options Overview Details

View History
  • Implied Volatility 519.35% (-21.04%)
  • Historical Volatility 74.69%
  • IV Percentile 87%
  • IV Rank 59.38%
  • IV High 863.60% on 04/30/26
  • IV Low 16.06% on 11/04/25
  • Expected Move (DTE 5) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 711
  • Open Int (30-Day) 517
  • Expected Range 3.37 to 3.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.00
  • Number of Estimates 1
  • High Estimate $0.00
  • Low Estimate $0.00
  • Prior Year $-1.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.52 +33.73%
on 05/19/26
3.95 -14.68%
on 05/29/26
+0.26 (+8.36%)
since 05/12/26
3-Month
2.15 +56.74%
on 04/01/26
3.95 -14.68%
on 05/29/26
+0.71 (+26.69%)
since 03/12/26
52-Week
2.15 +56.74%
on 04/01/26
5.27 -36.01%
on 06/13/25
-1.92 (-36.29%)
since 06/12/25

Most Recent Stories

More News
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -

BLRX : 3.37 (-2.88%)
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

TEL AVIV, Israel and OSLO, Norway , May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology...

BLRX : 3.37 (-2.88%)
BioLineRx to Report First Quarter 2026 Results on May 27, 2026

Management to Hold Conference Call at 8:30 a.m. EDT

BLRX : 3.37 (-2.88%)
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts

New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested

BLRX : 3.37 (-2.88%)
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center

BLRX : 3.37 (-2.88%)
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

GLIX1, a TET2 activator ,  is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma  and other cancers  

BLRX : 3.37 (-2.88%)
BioLineRx Reports 2025 Financial Results and Provides Corporate Update

- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -

BLRX : 3.37 (-2.88%)
BioLineRx to Report 2025 Annual Results on March 23, 2026

Management to Hold Conference Call at 8:30 a.m. EDT

BLRX : 3.37 (-2.88%)
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -

BLRX : 3.37 (-2.88%)
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Management to Hold Conference Call at 8:30 a.m. EST

BLRX : 3.37 (-2.88%)

Business Summary

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040,...

See More

Key Turning Points

3rd Resistance Point 3.75
2nd Resistance Point 3.68
1st Resistance Point 3.52
Last Price 3.37
1st Support Level 3.29
2nd Support Level 3.22
3rd Support Level 3.06

See More

52-Week High 5.27
Fibonacci 61.8% 4.08
Fibonacci 50% 3.71
Last Price 3.37
Fibonacci 38.2% 3.34
52-Week Low 2.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.